Terms: = Sarcomas AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Treatment
687 results:
1. USP3 promotes osteosarcoma progression via deubiquitinating EPHA2 and activating the PI3K/akt signaling pathway.
Li A; Wang S; Nie J; Xiao S; Xie X; Zhang Y; Tong W; Yao G; Liu N; Dan F; Shu Z; Liu J; Liu Z; Yang F
Cell Death Dis; 2024 Mar; 15(3):235. PubMed ID: 38531846
[TBL] [Abstract] [Full Text] [Related]
2. A recurrent NTRK1 tyrosine kinase domain mutation pair is characteristic in a subset of dedifferentiated liposarcomas.
Lippai Z; Péterfia B; Papp G; Dezső K; Bedics G; Pápai Z; Lamers MH; Kuin RC; Szuhai K; Sápi Z
Eur J Cancer; 2024 May; 202():114005. PubMed ID: 38531265
[TBL] [Abstract] [Full Text] [Related]
3. Screening for Synergistic Reagents With Pazopanib Against Osteosarcoma Using a Compound Library.
Yada Y; Asanuma K; Kakimto T; Okuno K; Okamoto T; Iino T; Nakamura T; Sudo A
Anticancer Res; 2024 Mar; 44(3):1071-1078. PubMed ID: 38423639
[TBL] [Abstract] [Full Text] [Related]
4. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.
Wang Y; Ma X; Xu E; Huang Z; Yang C; Zhu K; Dong Y; Zhang C
Clin Transl Med; 2024 Feb; 14(2):e1586. PubMed ID: 38372422
[TBL] [Abstract] [Full Text] [Related]
5. The role of high mobility group AT-hook 1 in viral infections: Implications for cancer pathogenesis.
Akade E; Jalilian S
Int J Biochem Cell Biol; 2024 Apr; 169():106532. PubMed ID: 38278412
[TBL] [Abstract] [Full Text] [Related]
6. Immune characteristics of dedifferentiated retroperitoneal liposarcomas and the reliability of regional samples in evaluating their tumor immune microenvironments.
Zhou C; Li M; Ren Y; Miao F; Wang Y; Wu T; Gou X; Li W
World J Surg Oncol; 2024 Jan; 22(1):25. PubMed ID: 38254190
[TBL] [Abstract] [Full Text] [Related]
7. Effect of traditional Chinese medicine in osteosarcoma: Cross-interference of signaling pathways and potential therapeutic targets.
Liu Y; Jiang B; Li Y; Zhang X; Wang L; Yao Y; Zhu B; Shi H; Chai X; Hu X; Zhang B; Li H
Medicine (Baltimore); 2024 Jan; 103(3):e36467. PubMed ID: 38241548
[TBL] [Abstract] [Full Text] [Related]
8. Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo.
Kong Y; Li X; Zhang H; Fu B; Jiang HY; Yang HL; Dai J
Cell Death Dis; 2024 Jan; 15(1):57. PubMed ID: 38228583
[TBL] [Abstract] [Full Text] [Related]
9. Mechanism of lysine oxidase-like 1 promoting synovial inflammation mediating rheumatoid arthritis development.
Hu J; Liu X; Xu Q; Zhu M; Wang S; Quan K; Dai M; Mo F; Zhan H
Aging (Albany NY); 2024 Jan; 16(1):928-947. PubMed ID: 38217541
[TBL] [Abstract] [Full Text] [Related]
10. A study protocol for an open-label, single-arm, single-center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma.
Huang H; Zhang H; Cao B
Thorac Cancer; 2024 Feb; 15(5):427-433. PubMed ID: 38211967
[TBL] [Abstract] [Full Text] [Related]
11. Soy isoflavones induces mitophagy to inhibit the progression of osteosarcoma by blocking the akt/mTOR signaling pathway.
Zheng Z; Zhao X; Yuan B; Jiang S; Yan R; Dong X; Yao Q; Liang H
Mol Med; 2024 Jan; 30(1):5. PubMed ID: 38191316
[TBL] [Abstract] [Full Text] [Related]
12. Exploration of anti‑osteosarcoma activity of asiatic acid based on network pharmacology and
Pang H; Wu H; Zhan Z; Wu T; Xiang M; Wang Z; Song L; Wei B
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186298
[TBL] [Abstract] [Full Text] [Related]
13. Solute carrier family 35 member A2 regulates mitophagy through the PI3K/akt/mTOR axis, promoting the proliferation, migration, and invasion of osteosarcoma cells.
Luo X; Zhang J; Guo C; Jiang N; Zhang F; Jiao Q; Xu K; Yang J; Qu G; Lv XB; Zhang Z
Gene; 2024 Mar; 898():148110. PubMed ID: 38151177
[TBL] [Abstract] [Full Text] [Related]
14. Caulis Spatholobi extracts inhibit osteosarcoma growth and metastasis through suppression of CXCR4/PI3K/akt signaling.
Jiang Y; Gao Y; Li X; He F; Liu Y; Wang R
J Orthop Surg Res; 2023 Dec; 18(1):985. PubMed ID: 38129870
[TBL] [Abstract] [Full Text] [Related]
15. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/akt/PI3K Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
16. Factors predictive of second-line chemotherapy in soft tissue sarcoma: An analysis of the National Genomic Profiling Database.
Mochizuki T; Ikegami M; Akiyama T
Cancer Sci; 2024 Feb; 115(2):575-588. PubMed ID: 38115234
[TBL] [Abstract] [Full Text] [Related]
17. KLK10 promotes the progression of KRAS mutant colorectal cancer via PAR1-PDK1-akt signaling pathway.
Wu K; Wu B; Yan K; Ding Q; Miao Z
Cell Biol Int; 2024 Apr; 48(4):440-449. PubMed ID: 38115179
[TBL] [Abstract] [Full Text] [Related]
18. Cirsiliol induces autophagy and mitochondrial apoptosis through the akt/FOXO1 axis and influences methotrexate resistance in osteosarcoma.
Luo M; Su Z; Gao H; Tan J; Liao R; Yang J; Lin L
J Transl Med; 2023 Dec; 21(1):907. PubMed ID: 38087310
[TBL] [Abstract] [Full Text] [Related]
19. Exploration in the Mechanism of Ginsenoside Rg5 for the treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.
Liu MY; Jiang DX; Zhao X; Zhang L; Zhang Y; Liu ZD; Liu RZ; Li HJ; Rong XY; Gao YZ
Orthop Surg; 2024 Feb; 16(2):462-470. PubMed ID: 38086608
[TBL] [Abstract] [Full Text] [Related]
20. Inhibition of PRL2 Upregulates PTEN and Attenuates Tumor Growth in Tp53-deficient Sarcoma and Lymphoma Mouse Models.
Nguele Meke F; Bai Y; Ruiz-Avila D; Carlock C; Ayub J; Miao J; Hu Y; Li Q; Zhang ZY
Cancer Res Commun; 2024 Jan; 4(1):5-17. PubMed ID: 38047587
[TBL] [Abstract] [Full Text] [Related]
[Next]
